Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lori M. Durgin
Observed name:
Lori Durgin
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
OpenAlex ID:
A5010934893
Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival
2020
·
Sri Harsha Tella
, Anuhya Kommalapati
, et al.
·
European Journal of Surgical Oncology
·
23
Survival and prognostic factors in patients with rectal squamous cell carcinoma
2020
·
Anuhya Kommalapati
, Sri Harsha Tella
, et al.
·
European Journal of Surgical Oncology
·
18
Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma
2018
·
Anuhya Kommalapati
, Sri Harsha Tella
, et al.
·
HPB
·
18
PDF
Survival and prognostic factors in patients with pancreatic squamous cell carcinoma
2019
·
Sri Harsha Tella
, Anuhya Kommalapati
, et al.
·
European Journal of Surgical Oncology
·
16
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma
2019
·
Sakti Chakrabarti
, Tyler J. Zemla
, et al.
·
The Oncologist
·
12
Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.
2020
·
Hao Xie
, Mitesh J. Borad
, et al.
·
Journal of Clinical Oncology
Consequences of Self-Objectification and Body Discrepancies
2014
·
Lori Durgin
·
Minds at UW (University of Wisconsin)
PDF
Show more works
View as search
Works count:
7
Citation count:
87
H-index:
5
I10-index:
5
Year
Topic
Type
